2026-2027 Request for Proposals
2026-2027 Request for Proposals supports established and young investigators advancing melanoma research to deliver near-term improvements in prevention, detection, diagnosis, and treatment.
Browse similar grants
Funder: Melanoma Research Alliance
Due Dates: August 21, 2026 (Established Investigator/AIP LOIs) | September 14, 2026 (Young Investigator eligibility materials) | November 5, 2026 (Young Investigator/Pilot proposals) | December 10, 2026 (Invited Established Investigator/AIP proposals)
Funding Amounts: At least $7.9 million across the cycle; individual awards up to $100,000–$375,000 over two or three years
Summary: Supports pre-clinical, translational, and early clinical research delivering high-impact, near-term advances in melanoma prevention, detection, diagnosis, and treatment.
Key Information: Each investigator may submit only one PI proposal across all mechanisms, including special opportunities.
Description
The Melanoma Research Alliance (MRA) funds research that translates scientific discoveries into tools and treatments for people with melanoma or at high risk. The 2026–2027 cycle supports Established Investigator, Academic-Industry Partnership, Young Investigator, and Pilot Awards. Projects may develop detection and diagnostic methods, validate diagnostic or prognostic biomarkers, translate findings into treatments, or identify factors that improve prevention strategies. Proposals with a clear path to near-term clinical application are strongly favored.
Special emphasis areas include rare melanoma subtypes, brain metastasis and leptomeningeal disease, biomarkers of treatment response or resistance, and biomarkers predicting progression of primary melanoma. Dedicated opportunities support acral and uveal melanoma research and UK- and Israel-based investigators. A separate Society of Surgical Oncology (SSO) partnership supports one Young Investigator Award.
